口服地屈孕酮能否改善自然周期冻胚移植日孕酮偏低的不良结局?
这项回顾性研究纳入886例未行黄体支持的自然周期冻胚移植患者,移植日血清孕酮<10 µg/l者(A组)自移植日起口服地屈孕酮,≥10 µg/l者(B组)多未行黄体支持。A组与B组持续妊娠率(47.5% vs 50.4%,P=0.51)、早期流产率(18.1% vs 19.6%,P=0.74)及活产率(46.5% vs 48.8%,P=0.60)均无显著差异。提示口服地屈孕酮可能避免移植日低孕酮的不良影响。
要点
- 移植日孕酮<10 µg/l者补充口服地屈孕酮后妊娠结局与孕酮正常者相当
- A组BMI显著高于B组(P<0.01),其余人口学特征基本可比
- 支持真自然与改良自然周期中个体化黄体支持策略
核心结论
- 自然周期冻胚移植日血清孕酮偏低时,口服地屈孕酮可能避免其对妊娠结局的不良影响。
研究设计与样本
- 单中心三级大学转诊中心回顾性研究,纳入886例移植前未行黄体支持的自然周期冻胚移植患者。
- 移植日血清孕酮<10 µg/l者为A组并自移植日起口服地屈孕酮,≥10 µg/l者为B组且多未行黄体支持。
主要发现
- 886例中160例(18%)移植日血清孕酮<10 µg/l。
- A组与B组持续妊娠率分别为47.5%与50.4%(P=0.51)。
- A组与B组早期流产率分别为18.1%与19.6%(P=0.74)。
- A组与B组活产率分别为46.5%与48.8%(P=0.60)。
- A组BMI显著高于B组(P<0.01),其余人口学特征基本可比。
临床怎么用
- 自然周期冻胚移植日检测血清孕酮,对<10 µg/l者可考虑自移植日起口服地屈孕酮进行个体化黄体支持。
局限性
- 回顾性设计,组间BMI存在显著差异,可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Is oral dydrogesterone administration associated with comparable pregnancy rates when suboptimal serum progesterone concentrations are identified on the day of transfer in true and modified natural-cycle frozen embryo transfer (NC-FET)? DESIGN: This retrospective study, conducted at a tertiary university-based referral centre, included 886 patients undergoing NC-FET without luteal phase support before FET who had serum progesterone measured on the day of transfer. Patients with serum progesterone <10 µg/l (group A) received oral dydrogesterone from the day of embryo transfer onward, whereas most patients with progesterone ≥10 µg/l (group B) received no luteal phase support. RESULTS: In total, 160/886 (18%) patients had serum progesterone <10 µg/l on the day of transfer. Demographic characteristics were largely comparable between groups, except for body mass index, which was significantly higher in group A (P < 0.01). Reproductive outcomes did not differ significantly: ongoing pregnancy rates were 47.5% and 50.4% for groups A and B (P = 0.51); early pregnancy loss occurred in 18.1% and 19.6%, respectively (P = 0.74); and live birth rates were 46.5% and 48.8% in groups A and B (P = 0.60). CONCLUSIONS: These findings suggest that the potentially deleterious impact of low serum progesterone on the day of blastocyst transfer in NC-FET cycles may be avoided when oral dydrogesterone is administered. This supports a personalized approach to luteal phase support in true and modified natural cycles.
引用
- Roelens C, Van Overberghe C, Aktoz F, et al. Can oral dydrogesterone mitigate adverse outcomes with low progesterone on transfer day in natural-cycle frozen embryo transfer? Reprod Biomed Online. 2026. PMID: 42119546. doi:10.1016/j.rbmo.2026.105546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。